Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950603 | 0.98 | NPC1 (0.59) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL27760768 | 0.94 | RAB9A (0.64) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29992900 | 0.94 | RAB9A (0.64) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28342829 | 0.92 | ACHE (0.58) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL17145052 | 0.90 | MAPT (0.70) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2614971 | 0.88 | MAPK14 (0.60) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18255986 | 0.88 | NPC1 (0.54) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL17144746 | 0.86 | NPC1 (0.53) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8090460 | 0.86 | ASIC3 (0.60) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30584739 | 0.86 | NPC1 (0.53) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (US) | 2018-07-10 | — | — | US | claimed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | claimed |
| WO-2015153252-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2015-10-08 | — | — | WO | claimed |
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | disclosed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | disclosed |
| WO-2015153252-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20100249431-A1 | PROCESS FOR MANUFACTURING DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALST, PROCESS FOR MANUFACTURING BETA-AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2208722-A1 | PROCESS FOR PRODUCTION OF DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALYST, PROCESS FOR PRODUCTION OF -AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE SALT | National University Corporation Nagoya University (JP) | 2010-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | FLT4, TUBB3, TUBA4A | NPC1 2308/4885RAB9A 1219/4885ALDH1A1 3306/4885 |
| US-20100249431-A1 | PROCESS FOR MANUFACTURING DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALST, PROCESS FOR MANUFACTURING BETA-AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE | MGAT2, MPST, MGAT1 | NPC1 4064/4885RAB9A 3592/4885ALDH1A1 213/4885 |
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | FLT4, TUBB3, TUBA4A | NPC1 2308/4885RAB9A 1219/4885ALDH1A1 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.